SEC Form 4 · accession 0001104659-15-002657
Radius Health, Inc. · RDUS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owners
Katherine Priestley
10% Owner
F2 Capital Ltd
10% Owner
F2 Bioscience IV L.P.
10% Owner
F2 Bioscience IV GP Ltd.
10% Owner
F2 Bio Ventures V L.P.
10% Owner
F2 Bio Ventures GP Ltd.
10% Owner
Globeways Holdings Ltd
10% Owner
Period of report
Jul 10, 2014
Accepted (ET)
Jan 15, 2015 · 5:04 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001428522
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | Jul 10, 2014 | J | 251,680 | — | D | 335,820 | I | By Fund |
| Common StockF1,F2 | Jul 15, 2014 | J | 335,820 | — | D | 0 | I | By Fund |
| Common StockF3 | holding | — | — | — | 1,794,983 | D | ||
| Common StockF4 | holding | — | — | — | 871,851 | I | By Fund |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Reflects a distribution by F2 Bioscience VI L.P. ("F2 Science") to a limited partner.
- F2The reported securities are owned directly by F2 Science. F2 Bioscience IV GP Ltd. ("F2 IV GP") is the General Partner of F2 Science. Katherine Priestley and Globeways Holdings Limited ("Globeways") are members of F2 IV GP. F2 Capital Limited ("F2 Capital") is an investment adviser to F2 Science. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F3The reported securities are owned directly by F2 Bioscience IV L.P. ("F2 IV"). F2 IV GP is the General Partner of F2 IV. Katherine Priestley and Globeways are members of F2 IV GP. F2 Capital is an investment adviser to F2 IV. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
- F4The reported securities are owned directly by F2 Bio Ventures V L.P. ("F2 Bio"). F2 Bio Ventures GP Ltd. is the General Partner of F2 Bio. Globeways is the sole member of F2 Bio Ventures GP Ltd. F2 Capital is an investment adviser to F2 Bio. Each of the reporting persons disclaims beneficial ownership of the securities reported herein except to the extent of their pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.